Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.

Interactions between antiepileptic drugs, or between antiepileptic drugs and other drugs, can be pharmacokinetic or pharmacodynamic in nature. Pharmacokinetic interactions involve changes in absorption, distribution or elimination, whereas pharmacodynamic interactions involve synergism and antagonism at the site of action. Most clinically important interactions of antiepileptic drugs result from induction or inhibition of drug metabolism. Carbamazepine, phenytoin, phenobarbital and primidone are strong inducers of cytochrome P450 and glucuronizing enzymes (as well as P-glycoprotein) and can reduce the efficacy of co-administered medications such as oral anticoagulants, calcium antagonists, steroids, antimicrobial and antineoplastic drugs through this mechanism. Oxcarbazepine, eslicarbazepine acetate, felbamate, rufinamide, topiramate (at doses ≥ 200 mg/day) and perampanel (at doses ≥ 8 mg/day) have weaker inducing properties, and a lower propensity to cause interactions mediated by enzyme induction. Unlike enzyme induction, enzyme inhibition results in decreased metabolic clearance of the affected drug, the serum concentration of which may increase leading to toxic effects. Examples of important interactions mediated by enzyme inhibition include the increase in the serum concentration of phenobarbital and lamotrigine caused by valproic acid. There are also interactions whereby other drugs induce or inhibit the metabolism of antiepileptic drugs, examples being the increase in serum carbamazepine concentration by erythromycin, and the decrease in serum lamotrigine concentration by oestrogen-containing contraceptives. Pharmacodynamic interactions between antiepileptic drugs may also be clinically important. These interactions can have potentially beneficial effects, such as the therapeutic synergism of valproic acid combined with lamotrigine, or adverse effects, such as the reciprocal potentiation of neurotoxicity observed in patients treated with a combination of sodium channel blocking antiepileptic drugs.

[1]  D. Tompson,et al.  The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. , 2014, Current clinical pharmacology.

[2]  Yoshiaki Yamamoto,et al.  Interaction between sulthiame and clobazam: Sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19 , 2014, Epilepsy & Behavior.

[3]  P. Crawford,et al.  Anti-Epileptic Drugs and Hormonal Treatments , 2014, Current Treatment Options in Neurology.

[4]  E. Perucca.  Optimizing antiepileptic drug treatment in tumoral epilepsy , 2013, Epilepsia.

[5]  W. K. Kennedy,et al.  Clinically Significant Drug Interactions with Atypical Antipsychotics , 2013, CNS Drugs.

[6]  P. Patsalos.  Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders , 2013, Clinical Pharmacokinetics.

[7]  P. Patsalos.  Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs , 2013, Clinical Pharmacokinetics.

[8]  G. Zaccara,et al.  Novel treatment options for epilepsy: focus on perampanel. , 2013, Pharmacological research.

[9]  M. Landrum,et al.  The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study , 2013, Epilepsy Research.

[10]  M. Brodie,et al.  Enzyme induction with antiepileptic drugs: Cause for concern? , 2013, Epilepsia.

[11]  J. Bobes,et al.  New treatment guidelines for acute bipolar mania: a critical review. , 2012, Journal of affective disorders.

[12]  Joo-Youn Cho,et al.  Reduced Valproic Acid Serum Concentrations Due to Drug Interactions With Carbapenem Antibiotics: Overview of 6 Cases , 2012, Therapeutic drug monitoring.

[13]  Hilde Lunde,et al.  Valproic Acid Significantly Lowers Serum Concentrations of Olanzapine—An Interaction Effect Comparable With Smoking , 2012, Therapeutic drug monitoring.

[14]  I. Bekersky,et al.  Pharmacokinetic Drug Interactions Between Clobazam and Drugs Metabolized by Cytochrome P450 Isoenzymes , 2012, Pharmacotherapy.

[15]  M. Miura,et al.  Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. , 2012, British journal of clinical pharmacology.

[16]  D. Clifford,et al.  Antiepileptic drug selection for people with HIV/AIDS: Evidence‐based guidelines from the ILAE and AAN , 2012, Epilepsia.

[17]  E. Perucca,et al.  Novel Medications for Epilepsy , 2011, Drugs.

[18]  K. Umemura,et al.  Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. , 2012, Drug metabolism and pharmacokinetics.

[19]  E. Perucca.  The Pharmacology of New Antiepileptic Drugs , 2011, CNS drugs.

[20]  R. Mirimanoff,et al.  Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma , 2011, Neurology.

[21]  W. Löscher,et al.  Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. , 2011, Current pharmaceutical design.

[22]  W. Bobo,et al.  A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. , 2011, The Journal of clinical psychiatry.

[23]  A. Weintrob,et al.  Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study , 2011, AIDS research and therapy.

[24]  E. Wijdicks,et al.  Valproic Acid and Warfarin: An Underrecognized Drug Interaction , 2011, Neurocritical care.

[25]  A. Sakamoto,et al.  Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy , 2011, Epilepsy Research.

[26]  E. Nutescu,et al.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update , 2011, Journal of Thrombosis and Thrombolysis.

[27]  Thaddaus R. Hellwig,et al.  Potential interaction between valproic acid and doripenem. , 2011, Current drug safety.

[28]  A. Kanner.  Depression and epilepsy: A bidirectional relation? , 2011, Epilepsia.

[29]  M. Backer,et al.  A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs , 2010, CNS drugs.

[30]  E. Perucca,et al.  Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy , 2010, Epilepsy Research.

[31]  J. Guillebaud,et al.  Contraception for women taking antiepileptic drugs , 2010, Journal of Family Planning and Reproductive Health Care.

[32]  S. Johannessen,et al.  Antiepileptic Drug Interactions - Principles and Clinical Implications , 2010, Current neuropharmacology.

[33]  D. Reddy.  Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives , 2010, Expert review of clinical pharmacology.

[34]  V. Laugel,et al.  The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy. , 2010, British journal of clinical pharmacology.

[35]  P. Patsalos,et al.  Drug interactions involving the new second- and third-generation antiepileptic drugs , 2010, Expert review of neurotherapeutics.

[36]  A. Falcão,et al.  Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. , 2010, Clinical therapeutics.

[37]  C. Timmer,et al.  Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[38]  B. Gidal,et al.  The Effect of Carbapenem Antibiotics on Plasma Concentrations of Valproic Acid , 2009, The Annals of pharmacotherapy.

[39]  E. Spina,et al.  Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder , 2009, Therapeutic drug monitoring.

[40]  J. Buckner,et al.  Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma , 2009, Neurology.

[41]  M. Brodie,et al.  Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo‐controlled trial , 2009, Epilepsia.

[42]  J. Łuszczki.  Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions , 2009 .

[43]  E. Perucca,et al.  Italian Consensus Conference on Epilepsy and Pregnancy, Labor and Puerperium , 2009, Epilepsia.

[44]  I. Leppik.  Treatment of epilepsy in the elderly , 2008, Current treatment options in neurology.

[45]  T. O'Brien,et al.  Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. , 2008, European journal of pharmacology.

[46]  T. Ketter.  Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. , 2008, The Journal of clinical psychiatry.

[47]  Jingdong Xie,et al.  Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy Subjects , 2008, Journal of clinical pharmacology.

[48]  E. Spina,et al.  Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  E. Perucca,et al.  Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy , 2008, Epilepsia.

[50]  Laszlo Endrenyi,et al.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. , 2008, British journal of clinical pharmacology.

[51]  Shufeng Zhou,et al.  Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring , 2007, Therapeutic drug monitoring.

[52]  O. Spigset,et al.  Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. , 2007, The Journal of clinical psychiatry.

[53]  V. Hiilesmaa,et al.  Epilepsy in pregnancy , 2007, BMJ : British Medical Journal.

[54]  D. J. Ennis,et al.  Open‐label steady‐state pharmacokinetic drug interaction study on co‐administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder , 2007, Human psychopharmacology.

[55]  C. D'Giano,et al.  ABC Transporters during Epilepsy and Mechanisms Underlying Multidrug Resistance in Refractory Epilepsy , 2007, Epilepsia.

[56]  J. Macher,et al.  Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine , 2007, Journal of clinical psychopharmacology.

[57]  O. Spigset,et al.  Effects of Comedication on the Serum Levels of Aripiprazole: Evidence from a Routine Therapeutic Drug Monitoring Service , 2007, Pharmacopsychiatry.

[58]  M. Hirata-Koizumi,et al.  Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA , 2007, Journal of clinical pharmacy and therapeutics.

[59]  E. Spina,et al.  Effect of Topiramate on Plasma Concentrations of Clozapine, Olanzapine, Risperidone, and Quetiapine in Patients With Psychotic Disorders , 2007, Clinical neuropharmacology.

[60]  Hitomi Mori,et al.  Interaction Between Valproic Acid and Carbapenem Antibiotics , 2007, Drug metabolism reviews.

[61]  S. Marino,et al.  Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. , 2007, International review of neurobiology.

[62]  A. J. van der Ven,et al.  Brief Report: Enzyme Inducers Reduce Elimination Half-Life After a Single Dose of Nevirapine in Healthy Women , 2006, Journal of acquired immune deficiency syndromes.

[63]  E. Perucca,et al.  Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder , 2006, Therapeutic drug monitoring.

[64]  E. Perucca,et al.  Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy , 2006, Epilepsia.

[65]  D. Burger,et al.  Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects , 2006, Clinical pharmacology and therapeutics.

[66]  Dieter Schmidt,et al.  Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.

[67]  J. Hallas,et al.  Trends in utilization of antiepileptic drugs in Denmark , 2006, Acta neurologica Scandinavica.

[68]  J. Ascher,et al.  Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. , 2006, British journal of clinical pharmacology.

[69]  E. Perucca.  British Journal of Clinical Pharmacology Clinically Relevant Drug Interactions with Antiepileptic Drugs , 2022 .

[70]  T. Mak,et al.  Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[71]  J. Sidhu,et al.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. , 2006, British journal of clinical pharmacology.

[72]  S. Grimm,et al.  Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. , 2006, British journal of clinical pharmacology.

[73]  E. Brodtkorb,et al.  Ethinyl Estradiol, Not Progestogens, Reduces Lamotrigine Serum Concentrations , 2005, Epilepsia.

[74]  Janne Kutschera Sund,et al.  Drug Interactions Between Lamotrigine and Psychoactive Drugs: Evidence From a Therapeutic Drug Monitoring Service , 2005, Journal of clinical psychopharmacology.

[75]  A. Herzog,et al.  Serum Valproate Levels with Oral Contraceptive Use , 2005, Epilepsia.

[76]  E. Spina,et al.  Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine , 2005, Epilepsia.

[77]  S. Czuczwar,et al.  Stiripentol . A novel antiepileptic drug , 2005 .

[78]  L. Citrome,et al.  Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate , 2005, Journal of clinical pharmacology.

[79]  M. Huttunen,et al.  Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report , 1994, Psychopharmacology.

[80]  P. Kwan,et al.  Overtreatment in Epilepsy , 2005, CNS drugs.

[81]  C. Marosi,et al.  P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy , 2005, Journal of Neuro-Oncology.

[82]  Y. Hassan,et al.  The complexity of achieving anticoagulation control in the face of warfarin – phenytoin interaction: an Asian case report , 2005, Pharmacy World and Science.

[83]  S. Rodenhuis,et al.  Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin , 2005, Cancer Chemotherapy and Pharmacology.

[84]  Derick R. Peterson,et al.  Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults , 2004, Antimicrobial Agents and Chemotherapy.

[85]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[86]  A. Gaedigk,et al.  Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction , 2004, Journal of acquired immune deficiency syndromes.

[87]  Simon Shorvon,et al.  Treatment of Epilepsy , 2004 .

[88]  R. Twyman,et al.  Pharmacokinetic Interactions of Topiramate , 2004, Clinical pharmacokinetics.

[89]  J. Tiihonen,et al.  Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial , 2003, Biological Psychiatry.

[90]  R. Sheth,et al.  Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy , 2003, Epilepsy Research.

[91]  T. Tomson,et al.  Oral contraceptives reduce lamotrigine plasma levels , 2003, Neurology.

[92]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs , 2003, The Lancet Neurology.

[93]  C. Vecht,et al.  Interactions between antiepileptic and chemotherapeutic drugs , 2003, The Lancet Neurology.

[94]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[95]  J. Borlak,et al.  Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects , 2003, European Journal of Clinical Pharmacology.

[96]  L. Balant,et al.  Therapeutic Drug Monitoring of Olanzapine: The Combined Effect of Age, Gender, Smoking, and Comedication , 2003, Therapeutic drug monitoring.

[97]  L. Stephen.  Drug Treatment of Epilepsy in Elderly People , 2003, Drugs & aging.

[98]  A. Suzuki,et al.  Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes , 2002, Psychopharmacology.

[99]  P. Patsalos,et al.  The Importance of Drug Interactions in Epilepsy Therapy , 2002, Epilepsia.

[100]  O. Pauwels.  Factors contributing to carbamazepine-macrolide interactions. , 2002, Pharmacological research.

[101]  J. Tanus-Santos,et al.  Implications of cytochrome P450 interactions when prescribing medication for hypertension. , 2002, Archives of internal medicine.

[102]  E. Perucca,et al.  Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs , 2002, Epilepsia.

[103]  R. Kim.  Drugs as P-glycoprotein substrates, inhibitors, and inducers , 2002, Drug metabolism reviews.

[104]  P. Peeters,et al.  Concomitant use of mirtazapine and phenytoin: a drug–drug interaction study in healthy male subjects , 2000, European Journal of Clinical Pharmacology.

[105]  E. Eliasson,et al.  Significant reduction of sertraline plasma levels by carbamazepine and phenytoin , 2002, European Journal of Clinical Pharmacology.

[106]  P. Uldall,et al.  Lamotrigine plasma levels reduced by oral contraceptives , 2001, Epilepsy Research.

[107]  C. Meyerhoff,et al.  Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin , 2001, Epilepsy Research.

[108]  A. Birnbaum,et al.  Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors , 2001, Epilepsy Research.

[109]  P. Thyrum,et al.  The Effects of Concomitant Phenytoin Administration on the Steady-State Pharmacokinetics of Quetiapine , 2001, Journal of clinical psychopharmacology.

[110]  C. Elger,et al.  Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy , 2000, Epilepsia.

[111]  E. Perucca,et al.  Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. , 2000, Therapeutic drug monitoring.

[112]  W. Kirch,et al.  Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects , 2000, European Journal of Clinical Pharmacology.

[113]  R. Anziano,et al.  The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. , 2000, British journal of clinical pharmacology.

[114]  R. Sachdeo,et al.  Coadministration of Phenytoin and Felbamate: Evidence of Additional Phenytoin Dose‐Reduction Requirements Based on Pharmacokinetics and Tolerability with Increasing Doses of Felbamate , 1999, Epilepsia.

[115]  O. Olesen,et al.  Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. , 1999, Therapeutic drug monitoring.

[116]  E. Perucca,et al.  Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. , 1998, Therapeutic drug monitoring.

[117]  J. Messenheimer.  Rash in Adult and Pediatric Patients Treated with Lamotrigine , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[118]  F. Camu,et al.  Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. , 1998, The Journal of antimicrobial chemotherapy.

[119]  R. Gerner,et al.  Lamotrigine toxicity secondary to sertraline , 1998, Seizure.

[120]  M. Jann,et al.  Elevated plasma clozapine concentrations after phenobarbital discontinuation. , 1998, The Journal of clinical psychiatry.

[121]  D. Berry,et al.  Carbamazepine Toxicity with Lamotrigine: Pharmacokinetic or Pharmacodynamic Interaction? , 1998, Epilepsia.

[122]  H. Bussey,et al.  A Review of Enzyme Induction of Warfarin Metabolism with Recommendations for Patient Management , 1997, Pharmacotherapy.

[123]  S. Tolbert,et al.  Elevated serum phenytoin concentrations associated with coadministration of sertraline. , 1997, Journal of clinical psychopharmacology.

[124]  R. Ramsay,et al.  Status epilepticus associated with the combination of valproic acid and clomipramine. , 1997, Therapeutic drug monitoring.

[125]  T. May,et al.  Influence of ethosuximide on valproic acid serum concentrations , 1997, Epilepsy Research.

[126]  R. Michelucci,et al.  Reduced Plasma Nisoldipine Concentrations in Phenytoin‐Treated Patients with Epilepsy , 1996, Epilepsia.

[127]  G. Anderson,et al.  Bidirectional interaction of valproate and lamotrigine in healthy subjects , 1996, Clinical pharmacology and therapeutics.

[128]  A. Eriksson,et al.  Pharmacokinetic Interactions Between Lamotrigine and Other Antiepileptic Drugs in Children with Intractable Epilepsy , 1996, Epilepsia.

[129]  G. Granneman,et al.  Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics , 1996, Clinical pharmacology and therapeutics.

[130]  P. Thürmann,et al.  Clinically Important Drug Interactions with Anticoagulants , 1996, Clinical pharmacokinetics.

[131]  O. Dulac,et al.  Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children , 1996, European Journal of Clinical Pharmacology.

[132]  G. Avanzini,et al.  Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients , 1995, Clinical pharmacokinetics.

[133]  P. Glue,et al.  Effects of felbamate on the pharmacokinetics of phenobarbital , 1995, Clinical pharmacology and therapeutics.

[134]  P. Thomas,et al.  [Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level]. , 1995, L'Encephale.

[135]  J. Tiihonen,et al.  Carbamazepine-induced changes in plasma levels of neuroleptics. , 1995, Pharmacopsychiatry.

[136]  I. Leppik,et al.  The effect of felbamate on valproic acid disposition , 1994, Clinical pharmacology and therapeutics.

[137]  P. Finley,et al.  Potential impact of valproic acid therapy on clozapine disposition , 1994, Biological Psychiatry.

[138]  L. Bertilsson,et al.  Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service , 1994, Therapeutic drug monitoring.

[139]  D. Israel,et al.  Warfarin-Felbamate Interaction: First Report , 1994, The Annals of Pharmacotherapy.

[140]  R. Baldessarini,et al.  Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. , 1994, The American journal of psychiatry.

[141]  B. Rambeck,et al.  Lamotrigine Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[142]  K. Brøsen,et al.  Concomitant intake of nortriptyline and carbamazepine. , 1993, Therapeutic drug monitoring.

[143]  B. Wroblewski,et al.  Potentially toxic serum concentrations of desipramine after discontinuation of valproic acid. , 1993, Brain injury.

[144]  B. Tettenborn,et al.  Oxcarbazepine Does Not Affect the Anticoagulant Activity of Warfarin , 1992, Epilepsia.

[145]  B. Weatherley,et al.  Sodium valproate acutely inhibits lamotrigine metabolism. , 1992, British journal of clinical pharmacology.

[146]  R. M. Tucker,et al.  Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[147]  M. Dam,et al.  No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin , 1991, Epilepsy Research.

[148]  C. Zucca,et al.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. , 1991, British journal of clinical pharmacology.

[149]  M. Jann,et al.  Increased carbamazepine plasma concentrations after fluoxetine coadministration , 1991, Clinical pharmacology and therapeutics.

[150]  G. Holmes,et al.  Discontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate , 1991, Epilepsia.

[151]  S. Preskorn,et al.  Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. , 1991, The Journal of clinical psychiatry.

[152]  G. Zaccara,et al.  Conventional vs controlled‐release carbamazepine: a multicentre, double‐blind, cross‐over study , 1990, Acta neurologica Scandinavica.

[153]  S. Schulz,et al.  Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia. , 1990, Journal of clinical psychopharmacology.

[154]  G. Bertschy,et al.  [Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. , 1990, L'Encephale.

[155]  G. Bertschy,et al.  Valpromide Increases the Plasma Concentrations of Amitriptyline and Its Metabolite Nortriptyline in Depressive Patients , 1988, Therapeutic drug monitoring.

[156]  S. Capewell,et al.  REDUCED FELODIPINE BIOAVAILABILITY IN PATIENTS TAKING ANTICONVULSANTS , 1988, The Lancet.

[157]  D. Greenblatt,et al.  Clonazepam pharmacokinetics, brain uptake, and receptor interactions. , 1987, The Journal of clinical psychiatry.

[158]  T. May,et al.  Serum concentrations of valproic acid: influence of dose and comedication. , 1985, Therapeutic drug monitoring.

[159]  R. Belmaker,et al.  Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia , 1985, Biological Psychiatry.

[160]  E. Perucca,et al.  Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. , 1985, Therapeutic drug monitoring.

[161]  James P. Worden,et al.  Phenytoin and nasogastric feedings , 1984, Neurology.

[162]  G. L. Cooper,et al.  Carbamazepine intoxication caused by interaction with isoniazid. , 1982, British medical journal.

[163]  O. Henriksen,et al.  Clinical and pharmacokinetic observations on sodium valproate – A 5‐year follow‐up study in 100 children with epilepsy , 1982, Acta neurologica Scandinavica.

[164]  E. Perucca.  Pharmacokinetic Interactions with Antiepileptic Drugs , 1982, Clinical pharmacokinetics.

[165]  P. Turner,et al.  INTERACTIONS OF ANTICONVULSANT DRUGS WITH MIANSERIN AND NOMIFENSINE , 1981, The Lancet.

[166]  S. Ahmad.  Drug interactions with oral anticoagulants , 1980, Postgraduate medicine.

[167]  H. W. Brown,et al.  Serum phenytoin after ethosuximide , 1978, Annals of neurology.

[168]  R. Cutler,et al.  Time‐course of interaction between carbamazepine and clonazepam in normal man , 1978, Clinical pharmacology and therapeutics.

[169]  A. Richens,et al.  Interaction between phenytoin and antacids. , 1978, British journal of clinical pharmacology.

[170]  P. Neuvonen,et al.  Interaction between Doxycycline and some Antiepileptic Drugs , 1974, British medical journal.

[171]  M. Rowland,et al.  Griseofulvin-phenobarbital interaction in man. , 1970, JAMA.

[172]  J. H. Marshall,et al.  Factors affecting chlorpromazine plasma levels in psychiatric patients. , 1970, Archives of general psychiatry.

[173]  Forrest Is,et al.  Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. , 1969 .

[174]  D. Robinson,et al.  Clinical observations of possible barbiturate interference with anticoagulation. , 1968, JAMA.